Stem cell combo shows promise for deadly transplant complication
NCT ID NCT07568535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding a stem cell therapy called remestemcel-L to the drug ruxolitinib can help adults with severe, steroid-resistant graft-versus-host disease (GVHD) after a bone marrow transplant. GVHD occurs when donor immune cells attack the patient's body. The study will enroll 180 participants and measure how many achieve a response by day 28 without needing extra immune-suppressing treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remestemcel-L (a type of stem cell) plus ruxolitinib
What this could lead to
If successful, this combination could offer a new treatment option for severe graft-versus-host disease, potentially improving survival and reducing the need for additional immune-suppressing drugs.
What could go wrong
This is an early-stage Phase 3 trial with only 180 participants, so results may not apply to everyone. The treatment involves stem cells and strong immune suppression, which carry risks of infection or other complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••